Anila Lingamneni - May 17, 2024 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP, Chief Technology Officer
Signature
/s/ Thomas V. Powers, attorney-in-fact for Ms. Lingamneni
Stock symbol
HAE
Transactions as of
May 17, 2024
Transactions value $
-$33,410
Form type
4
Date filed
5/21/2024, 05:55 PM
Previous filing
May 17, 2024
Next filing
May 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Tax liability -$33.4K -349 -3% $95.73 11.3K May 17, 2024 Direct F1, F2
transaction HAE Common Stock Award +3.39K +30.06% 14.7K May 17, 2024 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +7.46K $0.00 7.46K May 17, 2024 Common Stock 7.46K $95.73 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2 This number includes unvested RSUs previously reported.
F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F5 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.